Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

被引：0

作者：

Khoury, H. Jean ^{[1
]}

Kim, Dong-Wook ^{[2
]}

Zaritskey, Andrey ^{[3
]}

Gambacorti-Passerini, Carlo ^{[4
]}

Hochhaus, Andreas ^{[5
]}

Navarro, Juan ^{[6
]}

Rapoport, Aaron P. ^{[7
]}

Dorlhiac-Llacer, Pedro Enrique ^{[8
]}

Zanichelli, Maria ^{[9
]}

Kelly, Virginia ^{[10
]}

Besson, Nadine ^{[11
]}

McMullan, Trevor ^{[10
]}

Kantarjian, Hagop M. ^{[12
]}

Cortes, Jorge E. ^{[12
]}

机构：

[1] Emory Univ, Sch Med, Atlanta, GA USA

[2] Catholic Unvers Korea, Coll Med, Seoul St Marys Hosp, Catholic Blood & Marrow Transplantat Ctr,Dep Hema, Seoul, South Korea

[3] Univ Pavlov, St Petersburg, Russia

[4] Univ Milano Bicocca, Monza, Italy

[5] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[6] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru

[7] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[8] Hosp Clin FMUSP, Sao Paulo, Brazil

[9] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil

[10] Pfizer Inc, Cambridge, MA USA

[11] Wyeth Res, Paris, France

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：391 / 391

页数：1

共 50 条

[1] Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
Tiribelli, M.
Bonifacio, M.
Binotto, G.
Maino, E.
Calistri, E.
De Marchi, F.
Scaffidi, L.
Frison, L.
Medeot, M.
Ambrosetti, A.
Semenzato, G.
Fanin, R.
HAEMATOLOGICA, 2015, 100 : 132 - 132
[3] Nilotinib As Second or Third-Line Therapy for Myeloid Chronic Leukemia Chronic-Phase in Mexican Patients
Ayala, Manuel
Dominguez, Jacqueline
Chavez, Antonieta
BLOOD, 2016, 128 (22)
[4] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
Gambacorti-Passerini, C.
Cortes, J.
Zaritskey, A.
Bullorsky, E.
Navarro, J.
Khoury, H.
Besson, N.
McMullan, T.
Arkin, S.
Bruemmendorf, T.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
[5] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
Yood, Marianne Ulcickas
Oliveria, Susan A.
Cziraky, Mark
Hirji, Ishan
Hamdan, Muhammad
Davis, Catherine
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 213 - 219
[6] Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
袁婷
China Medical Abstracts(Internal Medicine), 2020, 37 (02) : 111 - 112
[7] Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy
Macalalad, Alexander R.
Chen, Lei
Guerin, Annie
Luo, Jiayuan
Wu, Eric Qiong
Griffin, James D.
BLOOD, 2012, 120 (21)
[8] Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study
Gambacorti-Passerini, Carlo
Khoury, H. Jean
Kantarjian, Hagop M.
Lipton, Jeffrey H.
Kim, Dong-Wook
Schafhausen, Philippe
Matczak, Ewa M.
Leip, Eric
Noonan, Kay
Bruemmendorf, Tim H.
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[9] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Khoury, H. Jean
Cortes, Jorge E.
Kantarjian, Hagop M.
Gambacorti-Passerini, Carlo
Baccarani, Michele
Kim, Dong-Wook
Zaritskey, Andrey
Countouriotis, Athena
Besson, Nadine
Leip, Eric
Kelly, Virginia
Bruemmendorf, Tim H.
BLOOD, 2012, 119 (15) : 3403 - 3412
[10] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli, Emilia
Caocci, Giovanni
Efficace, Fabio
Rizzo, Lorenzo
Colafigli, Gioia
Di Prima, Alessio
Pepe, Sara
Fegatelli, Danilo Alunni
Carmosino, Ida
Diverio, Daniela
Latagliata, Roberto
La Nasa, Giorgio
Martelli, Maurizio
Foa, Robin
Breccia, Massimo
ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1213 - 1219

← 1 2 3 4 5 →